Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Relapsed or Refractory B-cell Malignancies by CD19 Chimeric Antigen Receptor (CAR)-Modified T Cells

Next Previous
X
Search
Trial Profile

Treatment of Relapsed or Refractory B-cell Malignancies by CD19 Chimeric Antigen Receptor (CAR)-Modified T Cells

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti CD19 chimeric antigen receptor T cell therapy - Wuhan Sian Medical Technology (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell leukaemia; B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions

    • Most Recent Events

    • 12 Dec 2023 Results(n=130) presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 28 Feb 2019 Planned number of patients changed from 50 to 80.
    • 27 Nov 2017 Planned number of patients changed from 20 to 50.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top